Summary

The global Intramuscular Injection of Pain Medication market is projected to grow from US$ 2150 million in 2025 to US$ 3208 million by 2032, at a CAGR of 6.2% (2026-2032), driven by critical product segments and diverse end‑use applications. In 2025, the global production of intramuscular injection of pain medication reached approximately 768 million units, with an average global market price of around US$2.8 per unit. In the same year, the global total production capacity of intramuscular injection of pain medication reached 960 million units. The industry average gross profit margin of this product reached 47%. Intramuscular analgesics are drugs and preparations administered via intramuscular injection to relieve moderate to severe pain or acute pain requiring rapid onset of action. After injection into muscle tissue, the drugs are absorbed into the systemic circulation through the rich local capillary network. Compared to some oral preparations, they typically have a faster onset of action, avoid gastrointestinal absorption instability, and are suitable for patients who cannot take oral medication. Based on their pharmacological mechanisms, intramuscular analgesics can include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, and some centrally acting drugs or compound preparations with analgesic effects. Specific varieties vary depending on national drug registration, clinical guidelines, and prescription management regulations. These products are mainly used for perioperative pain, traumatic pain, acute musculoskeletal pain, renal colic, and other clinical scenarios requiring short-term rapid analgesia. The selection and administration of these drugs are usually determined by healthcare professionals based on the degree of pain, the patient's underlying condition, and the risks associated with medication. Special attention must be paid to the safety risks associated with different categories of drugs, including gastrointestinal, renal, cardiovascular, respiratory depression, and dependence. The upstream of the intramuscular injection analgesic drug industry chain mainly includes chemical raw materials, pharmaceutical excipients, water for injection, and pharmaceutical packaging materials. Among them, raw materials involve the corresponding analgesic active ingredients and their key intermediates, excipients include buffers, solubilizers, stabilizers, antioxidants, etc., and the packaging stage mainly uses pharmaceutical packaging products such as ampoules, vials, pre-filled syringes, rubber stoppers, and aluminum caps. The midstream consists of raw material manufacturers and injectable drug manufacturers. The core links cover raw material synthesis and purification, formulation development, aseptic preparation, filtration, filling, sterilization or aseptic production, quality testing, stability studies, and drug registration applications, which have high requirements for GMP management, aseptic production environment, and quality control system. The downstream is mainly used in hospitals, emergency centers, surgical centers, primary healthcare institutions, pain clinics, orthopedic departments, and other medical terminals, and is distributed by pharmaceutical commercial companies, professional drug distribution companies, and hospital pharmacies. Because some potent analgesics are strictly regulated or prescription drugs, their production, distribution, inventory, and clinical use are subject to rigorous supervision. Therefore, supply chain stability, product compliance, hospital access, centralized procurement, and coverage of clinical guidelines are crucial factors influencing a company's market competitiveness. The overall market for intramuscular analgesics is expected to maintain relatively stable clinical demand in the future, primarily driven by increased global surgical volume, a growing number of trauma and emergency patients, an aging population, and improved standardized management of perioperative and acute pain. At the same time, industry development is not simply reliant on increased use of traditional potent analgesics, but is gradually evolving towards safer, more precise, and multimodal analgesia. Clinical practice increasingly emphasizes stratified medication based on pain intensity and patient risk, and reduces unnecessary opioid exposure through NSAIDs, local anesthetics, and other non-opioid analgesic regimens. Therefore, injectable analgesics with rapid onset of action, stable efficacy, lower risk of gastrointestinal or central nervous system adverse reactions, and high ease of administration are expected to have significant growth potential. Prefilled formulations, unit-dose packaging, and products suitable for day surgery and rapid analgesia in emergency situations are also likely to see wider adoption. However, this market is also affected by factors such as consistency evaluation of injectable drugs, price competition of generic drugs, centralized procurement, strict regulation of opioids, and substitution of oral, intravenous, transdermal and local administration methods. In the future, the focus of competition among companies will be more on product safety, differentiated indications, formulation technology, cost control and hospital terminal coverage. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Intramuscular Injection of Pain Medication market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed. Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company Novartis Pfizer Sanofi Hengrui Medicine Hikma Pharmaceuticals Fresenius Kabi Baxter International Inc. Maruishi Pharmaceutical Co., Ltd. Ketorolac Tromethamine Injection Sun Pharmaceutical Industries Ltd. Humanwell Healthcare (Group) Co., Ltd. Yangtze River Pharmaceutical Group KRKA, d. d. Medochemie Ltd. Polpharma S.A. Gland Pharma Limited Sopharma AD Segment by Type Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Opioid Analgesics (Opioids) Local Anesthetics Others Segment by Analgesic Potency Medication for Mild-to-Moderate Pain Medication for Moderate-to-Severe Pain Medication for Severe Pain Segment by Duration of Analgesia <4 Hours 4–8 Hours 8 Hours Segment by Application Hospitals (Emergency Care, Surgery, and Inpatient Pain Management) Clinics (Outpatient Pain Treatment and Short-Term Procedures) Others (Emergency Medical Services, Nursing Care, and Other Medical Settings) Sales by Region North America U.S. Canada Mexico Asia-Pacific China Japan South Korea India China Taiwan Southeast Asia (Indonesia, Vietnam, Thailand) Europe Germany France U.K. Italy Russia Central and South America Brazil Argentina Rest of Central and South America Middle East, Africa Turkey Egypt GCC Countries South Africa Chapter Outline Chapter 1: Defines the Intramuscular Injection of Pain Medication study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Intramuscular Injection of Pain Medication: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Intramuscular Injection of Pain Medication Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
1.2.3 Opioid Analgesics (Opioids)
1.2.4 Local Anesthetics
1.2.5 Others
1.3 Market Segmentation by Analgesic Potency
1.3.1 Global Intramuscular Injection of Pain Medication Market Size by Analgesic Potency, 2021 vs 2025 vs 2032
1.3.2 Medication for Mild-to-Moderate Pain
1.3.3 Medication for Moderate-to-Severe Pain
1.3.4 Medication for Severe Pain
1.4 Market Segmentation by Duration of Analgesia
1.4.1 Global Intramuscular Injection of Pain Medication Market Size by Duration of Analgesia, 2021 vs 2025 vs 2032
1.4.2 <4 Hours
1.4.3 4–8 Hours
1.4.4 8 Hours
1.5 Market Segmentation by Application
1.5.1 Global Intramuscular Injection of Pain Medication Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Hospitals (Emergency Care, Surgery, and Inpatient Pain Management)
1.5.3 Clinics (Outpatient Pain Treatment and Short-Term Procedures)
1.5.4 Others (Emergency Medical Services, Nursing Care, and Other Medical Settings)
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Intramuscular Injection of Pain Medication Revenue Estimates and Forecasts (2021-2032)
2.2 Global Intramuscular Injection of Pain Medication Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Intramuscular Injection of Pain Medication Sales Estimates and Forecasts (2021-2032)
2.4 Global Intramuscular Injection of Pain Medication Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Intramuscular Injection of Pain Medication Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Intramuscular Injection of Pain Medication Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Market Share by Key Manufacturers
3.5.2 Opioid Analgesics (Opioids): Market Share by Key Manufacturers
3.5.3 Local Anesthetics: Market Share by Key Manufacturers
3.5.4 Others: Market Share by Key Manufacturers
3.6 Global Intramuscular Injection of Pain Medication Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Intramuscular Injection of Pain Medication Sales Performance by Type
4.1.1 Global Intramuscular Injection of Pain Medication Sales Volume by Type (2021-2032)
4.1.2 Global Intramuscular Injection of Pain Medication Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Intramuscular Injection of Pain Medication Sales Performance by Analgesic Potency
4.2.1 Global Intramuscular Injection of Pain Medication Sales Volume by Analgesic Potency (2021-2032)
4.2.2 Global Intramuscular Injection of Pain Medication Revenue by Analgesic Potency (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Analgesic Potency (2021-2032)
4.3 Global Intramuscular Injection of Pain Medication Sales Performance by Duration of Analgesia
4.3.1 Global Intramuscular Injection of Pain Medication Sales Volume by Duration of Analgesia (2021-2032)
4.3.2 Global Intramuscular Injection of Pain Medication Revenue by Duration of Analgesia (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Duration of Analgesia (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Intramuscular Injection of Pain Medication Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Intramuscular Injection of Pain Medication Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Intramuscular Injection of Pain Medication Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Intramuscular Injection of Pain Medication Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Intramuscular Injection of Pain Medication Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Intramuscular Injection of Pain Medication Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Intramuscular Injection of Pain Medication Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Intramuscular Injection of Pain Medication Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Intramuscular Injection of Pain Medication Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Intramuscular Injection of Pain Medication Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Intramuscular Injection of Pain Medication Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Intramuscular Injection of Pain Medication Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.1.4 Novartis Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Novartis Intramuscular Injection of Pain Medication Sales by Product in 2025
11.1.6 Novartis Intramuscular Injection of Pain Medication Sales by Application in 2025
11.1.7 Novartis Intramuscular Injection of Pain Medication Sales by Geographic Area in 2025
11.1.8 Novartis Intramuscular Injection of Pain Medication SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.2.4 Pfizer Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Pfizer Intramuscular Injection of Pain Medication Sales by Product in 2025
11.2.6 Pfizer Intramuscular Injection of Pain Medication Sales by Application in 2025
11.2.7 Pfizer Intramuscular Injection of Pain Medication Sales by Geographic Area in 2025
11.2.8 Pfizer Intramuscular Injection of Pain Medication SWOT Analysis
11.2.9 Pfizer Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.3.4 Sanofi Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Sanofi Intramuscular Injection of Pain Medication Sales by Product in 2025
11.3.6 Sanofi Intramuscular Injection of Pain Medication Sales by Application in 2025
11.3.7 Sanofi Intramuscular Injection of Pain Medication Sales by Geographic Area in 2025
11.3.8 Sanofi Intramuscular Injection of Pain Medication SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 Hengrui Medicine
11.4.1 Hengrui Medicine Corporation Information
11.4.2 Hengrui Medicine Business Overview
11.4.3 Hengrui Medicine Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.4.4 Hengrui Medicine Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Hengrui Medicine Intramuscular Injection of Pain Medication Sales by Product in 2025
11.4.6 Hengrui Medicine Intramuscular Injection of Pain Medication Sales by Application in 2025
11.4.7 Hengrui Medicine Intramuscular Injection of Pain Medication Sales by Geographic Area in 2025
11.4.8 Hengrui Medicine Intramuscular Injection of Pain Medication SWOT Analysis
11.4.9 Hengrui Medicine Recent Developments
11.5 Hikma Pharmaceuticals
11.5.1 Hikma Pharmaceuticals Corporation Information
11.5.2 Hikma Pharmaceuticals Business Overview
11.5.3 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.5.4 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Sales by Product in 2025
11.5.6 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Sales by Application in 2025
11.5.7 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Sales by Geographic Area in 2025
11.5.8 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication SWOT Analysis
11.5.9 Hikma Pharmaceuticals Recent Developments
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Corporation Information
11.6.2 Fresenius Kabi Business Overview
11.6.3 Fresenius Kabi Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.6.4 Fresenius Kabi Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Fresenius Kabi Recent Developments
11.7 Baxter International Inc.
11.7.1 Baxter International Inc. Corporation Information
11.7.2 Baxter International Inc. Business Overview
11.7.3 Baxter International Inc. Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.7.4 Baxter International Inc. Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Baxter International Inc. Recent Developments
11.8 Maruishi Pharmaceutical Co., Ltd.
11.8.1 Maruishi Pharmaceutical Co., Ltd. Corporation Information
11.8.2 Maruishi Pharmaceutical Co., Ltd. Business Overview
11.8.3 Maruishi Pharmaceutical Co., Ltd. Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.8.4 Maruishi Pharmaceutical Co., Ltd. Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Maruishi Pharmaceutical Co., Ltd. Recent Developments
11.9 Ketorolac Tromethamine Injection
11.9.1 Ketorolac Tromethamine Injection Corporation Information
11.9.2 Ketorolac Tromethamine Injection Business Overview
11.9.3 Ketorolac Tromethamine Injection Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.9.4 Ketorolac Tromethamine Injection Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Ketorolac Tromethamine Injection Recent Developments
11.10 Sun Pharmaceutical Industries Ltd.
11.10.1 Sun Pharmaceutical Industries Ltd. Corporation Information
11.10.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.10.3 Sun Pharmaceutical Industries Ltd. Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.10.4 Sun Pharmaceutical Industries Ltd. Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.11 Humanwell Healthcare (Group) Co., Ltd.
11.11.1 Humanwell Healthcare (Group) Co., Ltd. Corporation Information
11.11.2 Humanwell Healthcare (Group) Co., Ltd. Business Overview
11.11.3 Humanwell Healthcare (Group) Co., Ltd. Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.11.4 Humanwell Healthcare (Group) Co., Ltd. Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Humanwell Healthcare (Group) Co., Ltd. Recent Developments
11.12 Yangtze River Pharmaceutical Group
11.12.1 Yangtze River Pharmaceutical Group Corporation Information
11.12.2 Yangtze River Pharmaceutical Group Business Overview
11.12.3 Yangtze River Pharmaceutical Group Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.12.4 Yangtze River Pharmaceutical Group Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Yangtze River Pharmaceutical Group Recent Developments
11.13 KRKA, d. d.
11.13.1 KRKA, d. d. Corporation Information
11.13.2 KRKA, d. d. Business Overview
11.13.3 KRKA, d. d. Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.13.4 KRKA, d. d. Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 KRKA, d. d. Recent Developments
11.14 Medochemie Ltd.
11.14.1 Medochemie Ltd. Corporation Information
11.14.2 Medochemie Ltd. Business Overview
11.14.3 Medochemie Ltd. Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.14.4 Medochemie Ltd. Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Medochemie Ltd. Recent Developments
11.15 Polpharma S.A.
11.15.1 Polpharma S.A. Corporation Information
11.15.2 Polpharma S.A. Business Overview
11.15.3 Polpharma S.A. Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.15.4 Polpharma S.A. Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Polpharma S.A. Recent Developments
11.16 Gland Pharma Limited
11.16.1 Gland Pharma Limited Corporation Information
11.16.2 Gland Pharma Limited Business Overview
11.16.3 Gland Pharma Limited Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.16.4 Gland Pharma Limited Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Gland Pharma Limited Recent Developments
11.17 Sopharma AD
11.17.1 Sopharma AD Corporation Information
11.17.2 Sopharma AD Business Overview
11.17.3 Sopharma AD Intramuscular Injection of Pain Medication Product Models, Descriptions and Specifications
11.17.4 Sopharma AD Intramuscular Injection of Pain Medication Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 Sopharma AD Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Intramuscular Injection of Pain Medication Industry Chain
12.2 Intramuscular Injection of Pain Medication Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Intramuscular Injection of Pain Medication Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Intramuscular Injection of Pain Medication Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Intramuscular Injection of Pain Medication Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Intramuscular Injection of Pain Medication Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Analgesic Potency, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Duration of Analgesia, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Intramuscular Injection of Pain Medication Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Intramuscular Injection of Pain Medication Revenue by Region (US$ Million), 2021-2026
Table 7. Global Intramuscular Injection of Pain Medication Revenue by Region (US$ Million), 2027-2032
Table 8. Global Intramuscular Injection of Pain Medication Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Table 9. Global Intramuscular Injection of Pain Medication Sales by Region (K Units), 2021-2026
Table 10. Global Intramuscular Injection of Pain Medication Sales by Region (K Units), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Intramuscular Injection of Pain Medication Sales by Manufacturers (K Units), 2021-2026
Table 13. Global Intramuscular Injection of Pain Medication Sales Share by Manufacturers (2021-2026)
Table 14. Global Intramuscular Injection of Pain Medication Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Intramuscular Injection of Pain Medication Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Intramuscular Injection of Pain Medication Revenue, 2025
Table 18. Global Intramuscular Injection of Pain Medication Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Intramuscular Injection of Pain Medication Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 20. Key Manufacturers Intramuscular Injection of Pain Medication Manufacturing Base and Headquarters
Table 21. Global Intramuscular Injection of Pain Medication Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Intramuscular Injection of Pain Medication Sales Volume by Type (K Units), 2021-2026
Table 25. Global Intramuscular Injection of Pain Medication Sales Volume by Type (K Units), 2027-2032
Table 26. Global Intramuscular Injection of Pain Medication Revenue by Type (US$ Million), 2021-2026
Table 27. Global Intramuscular Injection of Pain Medication Revenue by Type (US$ Million), 2027-2032
Table 28. Global Intramuscular Injection of Pain Medication Sales Volume by Analgesic Potency (K Units), 2021-2026
Table 29. Global Intramuscular Injection of Pain Medication Sales Volume by Analgesic Potency (K Units), 2027-2032
Table 30. Global Intramuscular Injection of Pain Medication Revenue by Analgesic Potency (US$ Million), 2021-2026
Table 31. Global Intramuscular Injection of Pain Medication Revenue by Analgesic Potency (US$ Million), 2027-2032
Table 32. Global Intramuscular Injection of Pain Medication Sales Volume by Duration of Analgesia (K Units), 2021-2026
Table 33. Global Intramuscular Injection of Pain Medication Sales Volume by Duration of Analgesia (K Units), 2027-2032
Table 34. Global Intramuscular Injection of Pain Medication Revenue by Duration of Analgesia (US$ Million), 2021-2026
Table 35. Global Intramuscular Injection of Pain Medication Revenue by Duration of Analgesia (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Intramuscular Injection of Pain Medication Sales by Application (K Units), 2021-2026
Table 38. Global Intramuscular Injection of Pain Medication Sales by Application (K Units), 2027-2032
Table 39. Intramuscular Injection of Pain Medication High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Intramuscular Injection of Pain Medication Revenue by Application (US$ Million), 2021-2026
Table 41. Global Intramuscular Injection of Pain Medication Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Intramuscular Injection of Pain Medication Growth Accelerators and Market Barriers
Table 45. North America Intramuscular Injection of Pain Medication Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Intramuscular Injection of Pain Medication Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Intramuscular Injection of Pain Medication Growth Accelerators and Market Barriers
Table 48. Europe Intramuscular Injection of Pain Medication Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Intramuscular Injection of Pain Medication Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Intramuscular Injection of Pain Medication Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Intramuscular Injection of Pain Medication Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Intramuscular Injection of Pain Medication Growth Accelerators and Market Barriers
Table 53. Southeast Asia Intramuscular Injection of Pain Medication Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Intramuscular Injection of Pain Medication Investment Opportunities and Key Challenges
Table 55. Central and South America Intramuscular Injection of Pain Medication Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Intramuscular Injection of Pain Medication Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Intramuscular Injection of Pain Medication Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Novartis Corporation Information
Table 59. Novartis Description and Major Businesses
Table 60. Novartis Product Models, Descriptions and Specifications
Table 61. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 62. Novartis Sales Value Proportion by Product in 2025
Table 63. Novartis Sales Value Proportion by Application in 2025
Table 64. Novartis Sales Value Proportion by Geographic Area in 2025
Table 65. Novartis Intramuscular Injection of Pain Medication SWOT Analysis
Table 66. Novartis Recent Developments
Table 67. Pfizer Corporation Information
Table 68. Pfizer Description and Major Businesses
Table 69. Pfizer Product Models, Descriptions and Specifications
Table 70. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Pfizer Sales Value Proportion by Product in 2025
Table 72. Pfizer Sales Value Proportion by Application in 2025
Table 73. Pfizer Sales Value Proportion by Geographic Area in 2025
Table 74. Pfizer Intramuscular Injection of Pain Medication SWOT Analysis
Table 75. Pfizer Recent Developments
Table 76. Sanofi Corporation Information
Table 77. Sanofi Description and Major Businesses
Table 78. Sanofi Product Models, Descriptions and Specifications
Table 79. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Sanofi Sales Value Proportion by Product in 2025
Table 81. Sanofi Sales Value Proportion by Application in 2025
Table 82. Sanofi Sales Value Proportion by Geographic Area in 2025
Table 83. Sanofi Intramuscular Injection of Pain Medication SWOT Analysis
Table 84. Sanofi Recent Developments
Table 85. Hengrui Medicine Corporation Information
Table 86. Hengrui Medicine Description and Major Businesses
Table 87. Hengrui Medicine Product Models, Descriptions and Specifications
Table 88. Hengrui Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Hengrui Medicine Sales Value Proportion by Product in 2025
Table 90. Hengrui Medicine Sales Value Proportion by Application in 2025
Table 91. Hengrui Medicine Sales Value Proportion by Geographic Area in 2025
Table 92. Hengrui Medicine Intramuscular Injection of Pain Medication SWOT Analysis
Table 93. Hengrui Medicine Recent Developments
Table 94. Hikma Pharmaceuticals Corporation Information
Table 95. Hikma Pharmaceuticals Description and Major Businesses
Table 96. Hikma Pharmaceuticals Product Models, Descriptions and Specifications
Table 97. Hikma Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Hikma Pharmaceuticals Sales Value Proportion by Product in 2025
Table 99. Hikma Pharmaceuticals Sales Value Proportion by Application in 2025
Table 100. Hikma Pharmaceuticals Sales Value Proportion by Geographic Area in 2025
Table 101. Hikma Pharmaceuticals Intramuscular Injection of Pain Medication SWOT Analysis
Table 102. Hikma Pharmaceuticals Recent Developments
Table 103. Fresenius Kabi Corporation Information
Table 104. Fresenius Kabi Description and Major Businesses
Table 105. Fresenius Kabi Product Models, Descriptions and Specifications
Table 106. Fresenius Kabi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Fresenius Kabi Recent Developments
Table 108. Baxter International Inc. Corporation Information
Table 109. Baxter International Inc. Description and Major Businesses
Table 110. Baxter International Inc. Product Models, Descriptions and Specifications
Table 111. Baxter International Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Baxter International Inc. Recent Developments
Table 113. Maruishi Pharmaceutical Co., Ltd. Corporation Information
Table 114. Maruishi Pharmaceutical Co., Ltd. Description and Major Businesses
Table 115. Maruishi Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 116. Maruishi Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Maruishi Pharmaceutical Co., Ltd. Recent Developments
Table 118. Ketorolac Tromethamine Injection Corporation Information
Table 119. Ketorolac Tromethamine Injection Description and Major Businesses
Table 120. Ketorolac Tromethamine Injection Product Models, Descriptions and Specifications
Table 121. Ketorolac Tromethamine Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Ketorolac Tromethamine Injection Recent Developments
Table 123. Sun Pharmaceutical Industries Ltd. Corporation Information
Table 124. Sun Pharmaceutical Industries Ltd. Description and Major Businesses
Table 125. Sun Pharmaceutical Industries Ltd. Product Models, Descriptions and Specifications
Table 126. Sun Pharmaceutical Industries Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Sun Pharmaceutical Industries Ltd. Recent Developments
Table 128. Humanwell Healthcare (Group) Co., Ltd. Corporation Information
Table 129. Humanwell Healthcare (Group) Co., Ltd. Description and Major Businesses
Table 130. Humanwell Healthcare (Group) Co., Ltd. Product Models, Descriptions and Specifications
Table 131. Humanwell Healthcare (Group) Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Humanwell Healthcare (Group) Co., Ltd. Recent Developments
Table 133. Yangtze River Pharmaceutical Group Corporation Information
Table 134. Yangtze River Pharmaceutical Group Description and Major Businesses
Table 135. Yangtze River Pharmaceutical Group Product Models, Descriptions and Specifications
Table 136. Yangtze River Pharmaceutical Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Yangtze River Pharmaceutical Group Recent Developments
Table 138. KRKA, d. d. Corporation Information
Table 139. KRKA, d. d. Description and Major Businesses
Table 140. KRKA, d. d. Product Models, Descriptions and Specifications
Table 141. KRKA, d. d. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. KRKA, d. d. Recent Developments
Table 143. Medochemie Ltd. Corporation Information
Table 144. Medochemie Ltd. Description and Major Businesses
Table 145. Medochemie Ltd. Product Models, Descriptions and Specifications
Table 146. Medochemie Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Medochemie Ltd. Recent Developments
Table 148. Polpharma S.A. Corporation Information
Table 149. Polpharma S.A. Description and Major Businesses
Table 150. Polpharma S.A. Product Models, Descriptions and Specifications
Table 151. Polpharma S.A. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Polpharma S.A. Recent Developments
Table 153. Gland Pharma Limited Corporation Information
Table 154. Gland Pharma Limited Description and Major Businesses
Table 155. Gland Pharma Limited Product Models, Descriptions and Specifications
Table 156. Gland Pharma Limited Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Gland Pharma Limited Recent Developments
Table 158. Sopharma AD Corporation Information
Table 159. Sopharma AD Description and Major Businesses
Table 160. Sopharma AD Product Models, Descriptions and Specifications
Table 161. Sopharma AD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Sopharma AD Recent Developments
Table 163. Key Raw Materials Distribution
Table 164. Raw Materials Key Suppliers
Table 165. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 166. Milestones in Production Technology Evolution
Table 167. Distributors List
Table 168. Market Trends and Market Evolution
Table 169. Market Drivers and Opportunities
Table 170. Market Challenges, Risks, and Restraints
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources

List of Figures
Figure 1. Intramuscular Injection of Pain Medication Product Picture
Figure 2. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Product Picture
Figure 4. Opioid Analgesics (Opioids) Product Picture
Figure 5. Local Anesthetics Product Picture
Figure 6. Others Product Picture
Figure 7. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Analgesic Potency, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Medication for Mild-to-Moderate Pain Product Picture
Figure 9. Medication for Moderate-to-Severe Pain Product Picture
Figure 10. Medication for Severe Pain Product Picture
Figure 11. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Duration of Analgesia, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. <4 Hours Product Picture
Figure 13. 4–8 Hours Product Picture
Figure 14. 8 Hours Product Picture
Figure 15. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Hospitals (Emergency Care, Surgery, and Inpatient Pain Management)
Figure 17. Clinics (Outpatient Pain Treatment and Short-Term Procedures)
Figure 18. Others (Emergency Medical Services, Nursing Care, and Other Medical Settings)
Figure 19. Intramuscular Injection of Pain Medication Report Years Considered
Figure 20. Global Intramuscular Injection of Pain Medication Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 22. Global Intramuscular Injection of Pain Medication Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Intramuscular Injection of Pain Medication Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Intramuscular Injection of Pain Medication Sales (K Units), 2021-2032
Figure 25. Global Intramuscular Injection of Pain Medication Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Figure 26. Global Intramuscular Injection of Pain Medication Sales Market Share by Region (2021-2032)
Figure 27. Top 5 and Top 10 Manufacturers Intramuscular Injection of Pain Medication Sales Volume Market Share in 2025
Figure 28. Global Intramuscular Injection of Pain Medication Revenue-Based Market Share Ranking (2025)
Figure 29. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 30. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Opioid Analgesics (Opioids) Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Local Anesthetics Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Others Revenue-Based Market Share by Manufacturer in 2025
Figure 34. Global Intramuscular Injection of Pain Medication Sales Volume-Based Market Share by Type (2021-2032)
Figure 35. Global Intramuscular Injection of Pain Medication Revenue-Based Market Share by Type (2021-2032)
Figure 36. Global Intramuscular Injection of Pain Medication ASP by Type (US$/Unit), 2021-2032
Figure 37. Global Intramuscular Injection of Pain Medication Sales Volume-Based Market Share by Analgesic Potency (2021-2032)
Figure 38. Global Intramuscular Injection of Pain Medication Revenue-Based Market Share by Analgesic Potency (2021-2032)
Figure 39. Global Intramuscular Injection of Pain Medication ASP by Analgesic Potency (US$/Unit), 2021-2032
Figure 40. Global Intramuscular Injection of Pain Medication Sales Volume-Based Market Share by Duration of Analgesia (2021-2032)
Figure 41. Global Intramuscular Injection of Pain Medication Revenue-Based Market Share by Duration of Analgesia (2021-2032)
Figure 42. Global Intramuscular Injection of Pain Medication ASP by Duration of Analgesia (US$/Unit), 2021-2032
Figure 43. Global Intramuscular Injection of Pain Medication Sales Market Share by Application (2021-2032)
Figure 44. Global Intramuscular Injection of Pain Medication Revenue-Based Market Share by Application (2021-2032)
Figure 45. Global Intramuscular Injection of Pain Medication ASP by Application (US$/Unit), 2021-2032
Figure 46. North America Intramuscular Injection of Pain Medication Sales YoY (K Units), 2021-2032
Figure 47. North America Intramuscular Injection of Pain Medication Revenue YoY (US$ Million), 2021-2032
Figure 48. North America Top 5 Manufacturers Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) in 2025
Figure 49. North America Intramuscular Injection of Pain Medication Sales Volume (K Units) by Application (2021-2032)
Figure 50. North America Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) by Application (2021-2032)
Figure 51. US Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 52. Canada Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 53. Mexico Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 54. Europe Intramuscular Injection of Pain Medication Sales YoY (K Units), 2021-2032
Figure 55. Europe Intramuscular Injection of Pain Medication Revenue YoY (US$ Million), 2021-2032
Figure 56. Europe Top 5 Manufacturers Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) in 2025
Figure 57. Europe Intramuscular Injection of Pain Medication Sales Volume (K Units) by Application (2021-2032)
Figure 58. Europe Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) by Application (2021-2032)
Figure 59. Germany Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 60. France Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 61. U.K. Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 62. Italy Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 63. Russia Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 64. Asia-Pacific Intramuscular Injection of Pain Medication Sales YoY (K Units), 2021-2032
Figure 65. Asia-Pacific Intramuscular Injection of Pain Medication Revenue YoY (US$ Million), 2021-2032
Figure 66. Asia-Pacific Top 8 Manufacturers Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) in 2025
Figure 67. Asia-Pacific Intramuscular Injection of Pain Medication Sales Volume (K Units) by Application (2021-2032)
Figure 68. Asia-Pacific Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) by Application (2021-2032)
Figure 69. Indonesia Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 70. Japan Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 71. South Korea Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 72. China Taiwan Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 73. India Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 74. Central and South America Intramuscular Injection of Pain Medication Sales YoY (K Units), 2021-2032
Figure 75. Central and South America Intramuscular Injection of Pain Medication Revenue YoY (US$ Million), 2021-2032
Figure 76. Central and South America Top 5 Manufacturers Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) in 2025
Figure 77. Central and South America Intramuscular Injection of Pain Medication Sales Volume (K Units) by Application (2021-2032)
Figure 78. Central and South America Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) by Application (2021-2032)
Figure 79. Brazil Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 80. Argentina Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 81. Middle East, and Africa Intramuscular Injection of Pain Medication Sales YoY (K Units), 2021-2032
Figure 82. Middle East and Africa Intramuscular Injection of Pain Medication Revenue YoY (US$ Million), 2021-2032
Figure 83. Middle East and Africa Top 5 Manufacturers Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) in 2025
Figure 84. Middle East and Africa Intramuscular Injection of Pain Medication Sales Volume (K Units) by Application (2021-2032)
Figure 85. Middle East and Africa Intramuscular Injection of Pain Medication Sales Revenue (US$ Million) by Application (2021-2032)
Figure 86. GCC Countries Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 87. Turkey Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 88. Egypt Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 89. South Africa Intramuscular Injection of Pain Medication Revenue (US$ Million), 2021-2032
Figure 90. Intramuscular Injection of Pain Medication Industry Chain Mapping
Figure 91. Regional Intramuscular Injection of Pain Medication Manufacturing Base Distribution (%)
Figure 92. Global Intramuscular Injection of Pain Medication Production Market Share by Region (2021-2032)
Figure 93. Intramuscular Injection of Pain Medication Production Process
Figure 94. Regional Intramuscular Injection of Pain Medication Production Cost Structure
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed